A Phase 2 interventional study of Ramucirumab and Paclitaxel in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-29.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is the only one that started in 2009, is one of 14 in phase 2, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 115th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2009, is one of 73 in phase 2, and was the 62nd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers. The advanced stages are associated with poor survival rates, a median survival rate of approximately 3.9 months if left untreated.
Angiogenesis is a process for wound healing and restoring blood flow to tissues after injury. It is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis may be promoted by growth factors and in diseases such as cancer, where growth factors are over expressed, the body loses the ability to maintain a balanced angiogenesis. This may embellish the existing supplies of blood; potentially increasing the delivery of oxygen and nutrients supplies for cancer growth and survival.
Ramucirumab is an angiogenesis inhibitor; and is believed to block the promotion of the growth factor to form new blood vessels, thus reducing the blood supply to the cancer cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle). In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks.
Biological: Ramucirumab · Drug: Paclitaxel · Drug: Carboplatin
10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
Also known as: IMC-1121B, LY3009806
200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
Percentage of Participants Who Are Progression-free (PFS) at 6 Months
Data presented are the percentage of participants without disease progression or death at 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Time frame: 6 months
Summary of Participants Reporting Adverse Events
Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
Time frame: Baseline up to 32.5 months
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
Time frame: First dose to measured progressive disease or death due to any cause up to 32.5 months
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: First dose up to 32.5 months
Overall Survival (OS) at 1 Year
Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.
Time frame: First dose to 1 year
Progression-free Survival (PFS)
Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy.
Time frame: First dose to measured progressive disease or death due to any cause, up to 32.5 months
Overall Survival (OS)
Overall survival is defined as the time from the first dose of study medication to the date of death from any cause. Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.
Time frame: First dose to death due to any cause, up to 32.5 months
Serum Anti-Ramucirumab Antibody Assessment
The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.
Time frame: Week 15 (Cycle 5)
Maximum Concentration of Ramucirumab (Cmax)
Time frame: Week 18 (Cycle 6), at 1-Hour Post End of Infusion
| Milestone | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Started | 41 |
| Received any quantity of study drug | 40 |
| Completed | 39 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Enrolled but never treated | 1 |
Data presented are the percentage of participants without disease progression or death at 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
| percentage of participants | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Percentage of Participants Who Are Progression-free (PFS) at 6 Months | 59.0 (41.3 to 72.9) |
Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
| participants | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Any ramucirumab related TEAE | 34 |
| Any ramucirumab related Serious TEAE | 8 |
| Any ramucirumab related Grade >= 3 TEAE | 15 |
| Any TEAE Leading to Discontinuation of ramucirumab | 13 |
| TEAE Leading to Dose Modification of ramucirumab | 24 |
| Any ramucirumab related TEAE with Outcome of Death | 0 |
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
| percentage of participants | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) | 55.0 (38.5 to 70.7) |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
| months | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Duration of Response | 5.54 (4.27 to 8.21) |
Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.
| percentage of participants | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Overall Survival (OS) at 1 Year | 74.6 (57.9 to 85.4) |
Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy.
| months | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Progression-free Survival (PFS) | 7.85 (5.49 to 9.86) |
Overall survival is defined as the time from the first dose of study medication to the date of death from any cause. Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.
| months | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Overall Survival (OS) | 16.85 (14.82 to 28.58) |
The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.
| participants | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Serum Anti-Ramucirumab Antibody Assessment | 1 |
| micrograms/milliliter (mcg/mL) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Maximum Concentration of Ramucirumab (Cmax) | 372 ± 82.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab + Paclitaxel + Carboplatin | — | 19/40 (47.5%) | 40/40 (100%) |
| Event | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 4/40 |
| NEUTROPENIABlood and lymphatic system disorders | 2/40 |
| CATHETER SEPSISInfections and infestations | 2/40 |
| NAUSEAGastrointestinal disorders | 1/40 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/40 |
| VOMITINGGastrointestinal disorders | 1/40 |
| CHILLSGeneral disorders | 1/40 |
| FATIGUEGeneral disorders | 1/40 |
| INFUSION RELATED REACTIONGeneral disorders | 1/40 |
| CHOLECYSTITISHepatobiliary disorders | 1/40 |
| Event | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| FATIGUEGeneral disorders | 29/40 |
| NEUROPATHY PERIPHERALNervous system disorders | 27/40 |
| NAUSEAGastrointestinal disorders | 23/40 |
| ALOPECIASkin and subcutaneous tissue disorders | 23/40 |
| CONSTIPATIONGastrointestinal disorders | 16/40 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 16/40 |
| DIARRHOEAGastrointestinal disorders | 14/40 |
| VOMITINGGastrointestinal disorders | 14/40 |
| NEUTROPENIABlood and lymphatic system disorders | 13/40 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 13/40 |
Modified intent to treat population (mITT): All participants who received any quantity of study drug.
| Age, Categorical(Participants) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 27 |
| >=65 years | 13 |
| Sex: Female, Male(Participants) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Female | 25 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 37 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| White | 34 |
| Black or African American | 4 |
| Asian | 2 |
| Region of Enrollment(participants) | Ramucirumab + Paclitaxel + Carboplatin |
|---|---|
| United States | 36 |
| United Kingdom | 4 |
The record gives a start of Jan 2009, a primary completion of Oct 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 3 years 2 months after primary completion. A results delay was requested in Jul 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab
Carcinoma, Non-Small-Cell Lung →